Short interest for Silk Road Medical gives investors a sense of the degree to which investors are betting on the decline of Silk Road Medical's stock. Short interest data is updated every two weeks.

Silk Road Medical Stock (NASDAQ:SILK), Short Interest Report

Silk Road Medical

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy. The company generates all of its revenue in the United States.

News

Short Ideas

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

CPRX

SILK

As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks You May Want To Dump In Q1

SilkRoad Medical

Analyst Color

Upgrades

Health Care

Price Target

Analyst Ratings

Movers

General

Stifel&#39;s upgraded outlook on Silk Road Medical as CEO Chas McKhann addresses concerns, unveils a compelling vision, and outlines strategic initiatives. Analysts upgrade to Buy with $20 price target, citing confidence in TCAR technology and long-term growth under McKhann&#39;s leadership.

Heart Devices Focused Silk Road Medical Stock Gets an Upgrade - Analyst Says New CEO&#39;s Initiatives Sets Stage For &#39;Back On Track&#39;

Penny Stocks

Intraday Update

ABSI

ADAG

AGAE

AGFY

ALLY

ASTS

AXDX

AZTR

BCDA

BFRG

CELH

CHGG

CISS

CRGE

DTSS

ESPR

EWTX

GOOG

GOOGL

IRBT

KAMN

MESA

MESO

Morgan Stanley Capital Protected Notes for S&P 500 Index

NAMS

NKTX

ORGS

PCSA

PRTG

RNAZ

SAVE

SHPH

SMCI

SOAR

VMAR

WRLD

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session.

TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share.

TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Silk Road Medical Inc

SILK Laser Australia Ltd Ordinary Shares

SILK ENERGY LTD COM by SILK ENERGY LTD COM

Silk Energy Ltd

SILK ROAD ENTMT INC by Silk Road Entertainment, Inc.

Silk Road Entertainment Inc

Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.81) by 35.8 percent. This is a 48.57 percent decrease over losses of $(0.35) per share from the same period last year.

Earnings

Earnings Beats

IMNM

Immunome Q1 EPS $(0.52) Beats $(0.81) Estimate

LUCD

Lucid's Chairman And CEO Says We Strengthened Balance Sheet Closing ~$30M Preferred Stock Financing To Long-Term Investors; Extends Our Runway Past Milestones; EsoGuard Commercial Execution Continues To Deliver Results As We Drive Towards Expanded Private And Public Coverage, As Well As Direct Contracting

<ul>
<li>Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data &nbsp;</li>
<li>Crodafos&#x2122; CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair types</li>
<li>Findings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis &nbsp;</li>
</ul>
WESTLAKE VILLAGE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rhPtoca-jjnrLBZc8UCZoONn8iQ8SmxUz4pJVd5y8oP5PhoADMh0f3oQKpjMTq7olr3BacR9oMRtFipS4jrrM4ETwicCRToJm75rhg47vac=">Arcutis Biotherapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the <a href="https://www.globenewswire.com/Tracker?data=k95crNYLsygE_s6ctDAVfjF0orY-KsUOmJcripHR18_8aWjcn76BJPSW3GLcv8u9GvC3UrVa06dUZY9PQGz9vc97ryGhqrT68v-ZvL0kgqoiQ078vTY7ZboIfEMO3shSD1RPLdJhRuoNpFEPu2nxAmCmYEFvCyWjvsWzbt8lwHE=">Journal of Clinical and Aesthetic Dermatology&nbsp;(JCAD)</a> published the outcomes of a comprehensive evaluation by an expert dermatologist panel assessing the formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%. ZORYVE foam is a once-daily steroid-free treatment for <a href="https://www.globenewswire.com/Tracker?data=wJjHpkMrz8_bU1LM4Ih3uL2TIApl49DZao2-dqBsm4RTFiUaGyidDyq7cdY_rSoG5VxnZ9nXryDCYXtagCZjKIMFP7UODZ_focIfWtSKO1gR_k-5_DL22llXmcY0RtqnctjydNoL72_wtzvDRyuq0nQKLFkqpkadybY4hWjnSf8=">seborrheic dermatitis</a>.&nbsp;The published article supports the use of ZORYVE foam in all hair and skin types.

Biotech

ARQT

The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics' Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%

Jefferies analyst Blayne Curtis assumes NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy rating and raises Price Target to $1200.

Initiation

NVDA

Jefferies Assumes NVIDIA at Buy, Raises Price Target to $1200

AZUL

Azul Q1 Total Operating Revenue R$4.7B, Up 4.5% YoY; EBITDA R$1.4B, Up 37.4% YoY

<h3>Gainers</h3>
<ul>
<li>GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock rose 31.1% to $22.9 during Monday's pre-market session. The market value of their outstanding shares is at $7.0 billion. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares moved upwards by 19.2% to $0.35. The market value of their outstanding shares is at $57.0 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares rose 14.25% to $0.4. The company's market cap stands at $1.8 million. </li>
<li>Cazoo Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CZOO#NYSE">CZOO</a>) shares increased by 10.37% to $6.5. The company's market cap stands at $31.7 million. </li>
<li>Container Store Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TCS#NYSE">TCS</a>) shares increased by 9.89% to $1.0. The company's market cap stands at $51.6 million. </li>
<li>MGO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) stock rose 8.8% to $0.23. The market value of their outstanding shares is at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Barnes &amp; Noble Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) shares declined by 35.3% to $0.19 during Monday's pre-market session. The market value of their outstanding shares is at $9.9 million. </li>
<li>Visionary Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) stock decreased by 8.14% to $0.32. The market value of their outstanding shares is at $16.6 million. </li>
<li>Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares decreased by 7.28% to $1.53. The company's market cap stands at $4.7 million. </li>
<li>Selina Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) stock fell 6.67% to $0.05. The market value of their outstanding shares is at $25.8 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares decreased by 6.33% to $0.25. The market value of their outstanding shares is at $1.5 million. </li>
<li>Tandy Leather Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLF#NASDAQ">TLF</a>) stock decreased by 5.06% to $4.7. The company's market cap stands at $39.4 million. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNED

CJET

CZOO

JFBR

MGOL

SLNA

ZAPP

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) stock increased by 31.09% to $1.18. The company's market cap stands at $40.9 million. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock increased by 21.69% to $0.57. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) shares moved upwards by 18.08% to $43.69. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares increased by 15.07% to $1.45. The company's market cap stands at $23.3 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) shares rose 13.78% to $8.5. The market value of their outstanding shares is at $528.3 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock declined by 13.1% to $3.0 during Monday's pre-market session. The market value of their outstanding shares is at $2.5 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares declined by 12.81% to $0.22. The market value of their outstanding shares is at $4.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 12.06% to $1.24. The market value of their outstanding shares is at $7.5 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock fell 9.09% to $30.03. The company's market cap stands at $2.6 billion. The company's, Q1 earnings came out today. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares declined by 9.08% to $0.07. The company's market cap stands at $2.6 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock decreased by 8.89% to $0.2. The market value of their outstanding shares is at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

CCLD

DYNT

FTRE

FULC

INKT

SXTP

TARS

TVGN

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) shares rose 24.6% to $0.18 during Monday's pre-market session. The market value of their outstanding shares is at $11.4 million. As per the press release, Q1 earnings came out today. </li>
<li>JanOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) stock rose 17.95% to $4.73. The company's market cap stands at $42.4 million. </li>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares moved upwards by 10.59% to $0.46. The market value of their outstanding shares is at $5.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Freight Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) stock increased by 8.84% to $0.7. The company's market cap stands at $1.7 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock rose 7.75% to $1.25. The market value of their outstanding shares is at $21.7 million. </li>
<li>FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) stock moved upwards by 7.55% to $0.5. The company's market cap stands at $63.0 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Caravelle Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACO#NASDAQ">CACO</a>) shares declined by 19.4% to $0.58 during Monday's pre-market session. The company's market cap stands at $30.6 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) stock decreased by 17.81% to $1.57. The market value of their outstanding shares is at $10.5 million. As per the news, the FY earnings report came out yesterday. </li>
<li>iSun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) stock fell 12.01% to $0.13. </li>
<li>FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) shares fell 9.99% to $0.63. The company's market cap stands at $284.3 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) stock decreased by 9.68% to $1.12. The market value of their outstanding shares is at $67.4 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock declined by 6.4% to $0.53. The company's market cap stands at $8.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

CACO

DFLI

FCEL

FRGT

FTCI

HTOO

ISUN

KITT

WLGS

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ascent Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) stock rose 22.9% to $0.12 during Monday's pre-market session. The company's market cap stands at $2.5 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock increased by 15.58% to $0.34. The market value of their outstanding shares is at $4.4 million. </li>
<li>Squarespace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) shares rose 12.59% to $43.0. The company's market cap stands at $5.9 billion. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) stock rose 11.76% to $1.14. The market value of their outstanding shares is at $19.9 million. </li>
<li>Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) stock moved upwards by 9.51% to $3.28. The market value of their outstanding shares is at $158.5 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Rubicon Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBT#NYSE">RBT</a>) stock moved upwards by 9.1% to $0.26. The market value of their outstanding shares is at $13.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alpha Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) stock decreased by 17.4% to $4.0 during Monday's pre-market session. The company's market cap stands at $61.0 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) stock decreased by 15.99% to $2.26. The company's market cap stands at $8.5 million. </li>
<li>AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) stock decreased by 13.96% to $2.22. The company's market cap stands at $14.4 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) shares declined by 7.06% to $1.45. The company's market cap stands at $22.7 million. </li>
<li>SAI.TECH Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAI#NASDAQ">SAI</a>) shares fell 6.99% to $1.01. The market value of their outstanding shares is at $24.8 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares decreased by 6.49% to $0.07. The market value of their outstanding shares is at $7.7 million. As per the press release, Q1 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASTI

ATGL

BTCS

LIDR

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

SLNH

SQSP

12 Information Technology Stocks Moving In Monday's Pre-Market Session

Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) reported quarterly earnings of $0.37 per share. This is a 5.13 percent decrease over earnings of $0.39 per share from the same period last year. The company reported $2.07 million in sales this quarter. This is a 11.67 percent increase over sales of $1.85 million the same period last year.

RAND

Rand Capital Q1 Adj EPS $0.37 Down From $0.39 YoY, Sales $2.07M Up From $1.85M YoY

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present new efficacy data on brilaroxazine in an animal model of idiopathic pulmonary fibrosis as part of a late-breaking poster presentation at the 2024 American Thoracic Society (ATS) International Conference, to be held in San Diego, CA, May 17-22, 2024. &nbsp;
Details for the poster presentation can be found below:
Title: Effectiveness of brilaroxazine on functional and underlying pathological inflammation and fibrosis parameters in bleomycin-induced idiopathic pulmonary fibrosis model using male sprague dawley rats Poster Number: 15059 Session (C73): Thematic Poster Session - Preclinical modeling of pulmonary inflammation and emphysema Date: Tuesday, May 21, 2024 Time: 9:15am – 4:15pm PT Presenter: Laxminarayan Bhat, Reviva Pharmaceuticals Location: San Diego Convention Center, San Diego, CA

RVPH

Reviva To Present New Preclinical Efficacy Data On Brilaroxazine In Idiopathic Pulmonary Fibrosis At 2024 ATS International Conference In San Diego, CA, May 17-22, 2024

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Group Expands Partnership With  Beijing Houji Insurance Brokerage

COCP

Cocrystal Pharma Q1 2024 EPS $(0.39) Up From $(0.64) YoY

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) with a Buy and maintains $47 price target.

Reiteration

Tempest Therapeutics, Inc. - Common Stock

TPST

HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target

The Nasdaq 100 closed higher by around 0.3% on Friday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Tidewater</h3>
<ul>
<li>The Trade: Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) Director Robert Robotti &lt;a href=&#8221;https://www.benzinga.com/sec/insider-trades/&#8221;&gt;&lt;em&gt; sold a total of 156,494 shares &lt;/em&gt;&lt;/a&gt; at an average price of $107.21. The insider received around $16.78 million from selling those shares.</li>
<li>What's Happening: On May 2, Tidewater reported better-than-expected first-quarter EPS and sales.</li>
<li>What Tidewater Does: Tidewater Inc provides offshore service vessels and marine support services to the offshore energy industry through the operation of a diversified fleet of marine service vessels.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">JPMorgan Chase</h3>
<ul>
<li>The Trade: JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) Head of Human Resources Robin Leopold <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 3,000 shares</a> at an average price of $198.86. The insider received around $596,576 from selling those shares.</li>
<li>What's Happening: JP Morgan Chase, during April, inaugurated a new Community Center branch in the Grand Concourse neighborhood of the Bronx.</li>
<li>What JPMorgan Chase Does: JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $3.9 trillion in assets.</li>
</ul>
<h3 class="wp-block-heading">Global Payments</h3>
<ul>
<li>The Trade: Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) Senior Executive VP and CHRO Andrea M Carter <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 3,300 shares</a> at an average price of $111.34. The insider received around $367,422 from selling those shares.</li>
<li>What's Happening: On May 1, Global Payments reported first-quarter financial results and issued guidance.</li>
<li>What Global Payments Does: Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants.</li>
</ul>
<h3 class="wp-block-heading">Teradata</h3>
<ul>
<li>The Trade: Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) Chief Customer Officer Michael D Hutchinson <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 18,500 shares</a> at an average price of $32.96. The insider received around $609,797 from selling those shares.</li>
<li>What's Happening: On May 6, Teradata reported mixed first-quarter financial results and issued second-quarter guidance.</li>
<li>What Teradata Does: Teradata Corp provides analytic data products and related services.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/05/38759538/how-to-earn-500-a-month-from-home-depot-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Home Depot Stock Ahead Of Q1 Earnings</a>

Insider Trades

JPMorgan, Global Payments And 2 Other Stocks Insiders Are Selling

Management

V2X, Inc. Appoints Jeremy Wensinger As President And CEO

Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 12.5 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $1.001 million which missed the analyst consensus estimate of $1.046 million by 4.33 percent. This is a 124.44 percent increase over sales of $446.000 thousand the same period last year.

Earnings Misses

Lucid Diagnostics Q1 2024 Adj EPS $(0.21) Beats $(0.27) Estimate, Sales $1.001M Miss $1.046M Estimate

Jefferies analyst Blayne Curtis downgrades Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from Buy to Hold and lowers the price target from $215 to $210.

Downgrades

AMAT

Jefferies Downgrades Applied Mat to Hold, Lowers Price Target to $210

GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) reported quarterly losses of $(0.46) per share. This is a 98.77 percent increase over losses of $(37.31) per share from the same period last year.

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Q1 EPS $(0.46) Up From $(37.31) YoY

LPSN

Avaya And LivePerson Partner To Create Omnichannel Solution

Argus upgrades Silk Road Medical to buy, cites expanding footprint

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silk Road Medical (SILK – Research Report) and Arcel...

Analysts Are Bullish on Top Healthcare Stocks: Silk Road Medical (SILK), Arcellx Inc (ACLX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silk Road Medical (SILK – Research Report) and Vieme...

Analysts Offer Insights on Healthcare Companies: Silk Road Medical (SILK) and Viemed Healthcare (VMD)

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Silk Road Medical (SILK – Research Report), with a price tar...

Lake Street Keeps Their Buy Rating on Silk Road Medical (SILK)

Silk Road Medical GAAP EPS of -$0.36 beats by $0.04, revenue of $48.5M beats by $3.81M

Silk Road Medical, Inc (SILK) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Silk Road Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/silk-stock-quote/">SILK</a>) just reported results for the first quarter of 2024.<ul><li>Silk Road Medical reported earnings per share of -36 cents. This was above the analyst estimate for EPS of -40 cents.</li><li>The company reported revenue of $48.48 million.</li><li>This was 8.51% better than the analyst estimate for revenue of $44.68 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/silk-stock-earnings-silk-road-medical-for-q1-of-2024/">SILK Stock Earnings: Silk Road Medical Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SILK Stock Earnings: Silk Road Medical Beats EPS, Beats Revenue for Q1 2024

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Silk Road Medical (SILK – Research Report) today and set a price target of $25.00. The c...

Oppenheimer Reaffirms Their Buy Rating on Silk Road Medical (SILK)

In a report released today, Travis Steed from Bank of America Securities maintained a Sell rating on Silk Road Medical (SILK – Research Report). Th...

Bank of America Securities Reaffirms Their Sell Rating on Silk Road Medical (SILK)

In a report released today, Adam Maeder from Piper Sandler maintained a Hold rating on Silk Road Medical (SILK – Research Report), with a price tar...

Piper Sandler Sticks to Their Hold Rating for Silk Road Medical (SILK)

ACLX

Legal

Press Releases

Silk Road Medical (SILK) Stock Tanks After Revenues Lowered and CEO Leaves – Hagens Berman

Silk Road Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System

Contracts

Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS

Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Silk Road Medical Stock (NASDAQ:SILK), Short Interest Report

People Also Watch